

Serum S100B and LDH at baseline and during therapy predict the outcome of metastatic melanoma patients treated with BRAF inhibitors

Running heading

S100B and LDH predict the outcome of melanoma patients treated with BRAF inhibitors

Authors

Maximilian Gassenmaier, MD^{1*}, Max M. Lenders, MD^{1*}, Andrea Forschner, MD¹, Ulrike Leiter, MD¹, Benjamin Weide, MD¹, Claus Garbe, MD¹, Thomas K. Eigentler, MD¹, Nikolaus B. Wagner, MD^{1,2}

Affiliations

¹Department of Dermatology, University Hospital Tübingen, Tübingen, Germany

²Department of Dermatology and Allergology, Kantonsspital St. Gallen, St. Gallen, Switzerland


*These authors contributed equally to this work.

Corresponding author

Nikolaus B. Wagner, MD; Department of Dermatology and Allergology, Kantonsspital St. Gallen, Rorschacherstrasse 95, CH-9007 St. Gallen, Switzerland, phone: +41 71 494 20 30, fax: +41 71 494 73 42, email: nikolausbenjamin.wagner@kssg.ch.

ORCID ID: 0000-0003-4708-2886

Supplementary Fig. S1



Supplementary Fig. S1 Schematic time line of blood draws

Median time points of blood draws at the indicated visits.

Abbreviations: BL, baseline; BR, best response; FV, first visit; PD, progressive disease; pPD, prior to PD.